A novel transforming growth factor β receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2850-2860

  Kawajiri, Hidemi ^a   Yashiro, Masakazu ^a   Shinto, Osamu ^a   Nakamura, Kazunori ^a   Tendo, Masashige ^a   Takemura, Satoru ^a   Node, Manabu ^b   Hamashima, Yoshio ^b   Kajimoto, Tetsuya ^b   Sawada, Tetsuji ^a   Ohira, Masaichi ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A 77; ALPHA2 INTEGRIN; ALPHA3 INTEGRIN; ALPHA5 INTEGRIN; PHOSPHOTRANSFERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; A 77 COMPOUND; A-77 COMPOUND; ANTINEOPLASTIC AGENT; INTEGRIN; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; SMAD2 PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; DRUG STRUCTURE; FEMALE; FIBROBLAST; FIBROSIS; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL TIME; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; METASTASIS; MORTALITY; NUDE MOUSE; PERITONEUM TUMOR; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, SCIRRHOUS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PERITONEAL NEOPLASMS; PHOSPHORYLATION; PYRAZOLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SMAD2 PROTEIN; STOMACH NEOPLASMS;

EID: 52049088285     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1634     Document Type: Article

References (34)

1. Otsuji E, Kuriu Y, Okamoto K, et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg 2004;188:327-32.
2. Kunisaki C, Shimada H, Nomura M, et al. Therapeutic strategy for scirrhous type gastric cancer. Hepatogas-troenterology 2005;52:314-8.
3. Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res 2003;63:8848-52.
4. Ikeguchi M, Yamamoto O, Kaibara N. Management protocol for scirrhous gastric cancer. In Vivo 2004;18:577-80.
5. Chen CY, Wu CW, Lo SS, Hsieh MC, Lui WY, Shen KH. Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology 2002;49:874-7.
6. Nakamura K, Yashiro M, Matsuoka T, et al. A novel molecular targeting compound as K-samll/FGF-R2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 2006;131:1530-41.
7. 1-integrin in the peritoneal implantation of scirrhous gastric carcinoma. Br J Cancer 1996;74:1406-12.
8. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 1995;72:1200-10.
9. 1-integrin in the peritoneal dissemination of human gastric carcinoma. Int J Mol Med 2000;5:21-5.
10. Kinugasa S, Abe S, Tachibana M, et al. Overexpression of transforming growth factor-β1 in scirrhous carcinoma of the stomach correlates with decreased survival. Oncology 1998;55:582-7.
11. Inoue T, Chung YS, Yashiro M, et al. Transforming growth factor-β and hepatocyte growth factor produced by gastric fibroblasts stimulate the invasiveness of scirrhous gastric cancer cells. Jpn J Cancer Res 1997;88:152-9.
12. Koyama T, Yashiro M, Inoue T, Nishimura S, Hirakawa YSCK. TGF-β1 secreted by gastric fibroblasts up-regulates CD44H expression and stimulates the peritoneal metastatic ability of scirrhous gastric cancer cells. Int J Oncol 2000;16:355-62.
13. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
14. Miyazono K, Suzuki H, Imamura T. Regulation of TGF-β signaling and its roles in progression of tumors. Cancer Sci 2003;94:230-4.
15. 1 integrin (VLA-3). Clin Exp Metastasis 2002;19:127-34.
16. 1 integrin (VLA-3). Cancer Res 2004;64:6065-70.
17. Benigni A, Zoja C, Corna D, et al. Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003;14:1816-24.
18. Bogdahn U, Hau P, Brawanski A, et al. Specific therapy for high-grade glioma by convention-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP-12009. Am Soc Clin Oncol Ann Meet. Abstract 1514; 2004.
19. Kano MR, Bae Y Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci U S A 2007;104:3460-5.
20. Cao Z, Flanders KC, Bertolette D, et al. Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-β and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 2003;101:498-507.
21. Feng XH, Derynck R. Specificity and versatility in tgf-β signaling through Smads. Annu Rev Cell Dev Biol 2005;21:659-93.
22. Reissmann E, Jornvall H, Blokzijl A, et al. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev 2001;15:2010-22.
23. Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K. Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 2002;7:1191-204.
24. Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 2003;46:3953-6.
25. Tojo M, Hamashima Y, Hanyu A, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-β. Cancer Sci 2005;96:791-800.
26. Nomura H, Nishimori H, Yasoshima T, et al. A novel experimental mouse model of peritoneal dissemination of human gastric cancer cells: analysis of the mechanism of peritoneal dissemination using cDNA macroarrays. Jpn J Cancer Res 2001;92:748-54.
27. Morozevich GE, Kozlova NI, Preobrazhenskaya ME, et al. The rote of β1 integrin subfamily in anchorage-dependent apoptosis of breast carcinoma cells differing in multidrug resistance. Biochemistry (Mosc) 2006;71:489-95.
28. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
29. Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFβ1 responses in human proximal-tubule epithelial cells. Biochem J 2006;393:601-7.
30. 1 function by RGD peptide homologues. J Biol Chem 1991;266:3579-85.
31. Matsuoka T, Hirakawa K, Chung YS, et al. Adhesion polypeptides are useful for the prevention of peritoneal dissemination of gastric cancer. Clin Exp Metastasis 1998;16:381-8.
32. 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000;87:336-42.
33. Nishimura S, Hirakawa-Chung KY, Yashiro M, et al. TGF-β1 produced by gastric cancer cells affects mesothelial cell morphology in peritoneal dissemination. Int J Oncol 1998;12:847-51.
34. Hawinkels LJ, Verspaget HW, van Duijn W, et al. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients. Br J Cancer 2007;97:398-404.